Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. owise4eu

OWISE4EU

OWise for Europe - A feasibility study of a pan-European mobile app providing people with cancer with useful tools and treatment information in one easily accessible place.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 OWISE4EU project word cloud

Explore the words cloud of the OWISE4EU project. It provides you a very rough idea of what is the project "OWISE4EU" about.

clinical    data    20    independently    launched    collected    pharmaceutical    126    people    30    benefit    validated    platform    swiftly    outcome    hospital    changer    reaching    care    insights    issue    countries    shown    engaged    roll    business    preferably    doctor    clear    types    quality    groups    supporting    accurately    aid    connecting    game    owise    interaction    understand    outcomes    pro    companies    70    patient    px    gt    big    oncology    life    first    winning    receive    app    expressed    prescribed    revenues    insurers    netherlands    initially    breast    adjust    analytics    bn    reduce    employ    plans    worldwide    phases    physicians    model    uk    annually    plan    medical    customised    incidence    treatment    healthcare    health    patients    reported    2020    revenue    least    million    actively    stands    award    treatments    cancer    visits    licensing    diagnosed    clinicians    mobile    anonymised    payers    generates   

Project "OWISE4EU" data sheet

The following table provides information about the project.

Coordinator		 PX HEALTHCARE BV 

Organization address
address: MUIDERSTRAAT 1
city: AMSTERDAM
postcode: 1011 PZ
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Netherlands [NL]
 Project website https://ec.europa.eu/easme/en/sme/8476/owise-europe-feasibility-study-pan-european-mobile-app-providing-people-cancer-useful-tools
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.4. (Active ageing and self-management of health)
2. H2020-EU.2.1.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT))
3. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
4. H2020-EU.3.1.6. (Health care provision and integrated care)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-03-01   to  2016-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    PX HEALTHCARE BV NL (AMSTERDAM) coordinator 50˙000.00

Map

 Project objective

Cancer is a big issue worldwide with 70% increase in incidence in the next 20 years. Around 3 million people are diagnosed with cancer in Europe annually and it costs the EU more than €126 bn/yr. To improve clinical outcomes of treatments, to reduce side-effects and to increase patients’ quality of life we need to accurately understand how patients experience cancer treatments.

Px HealthCare (also called Px, which stands for Patient Experience) has developed OWise, an independently validated, mobile medical platform supporting cancer patients during treatment. OWise is a real game-changer as - its award-winning app was shown to improve both patient experience and the patient-doctor interaction - while the fully anonymised Patient Reported Outcome data (PRO) are collected and investigated using advanced data-analytics to improve oncology outcomes. As OWise is prescribed by physicians, it is the first oncology platform connecting patients, physicians and payers with the clear potential to benefit all 3 groups. OWise is a novel way for patients to be actively engaged in their treatment and receive customised medical support. It is also a new way for clinicians to receive PRO data and to adjust treatment in between hospital visits. Px’ revenue model is based on licensing insights it generates from the PRO data to health care insurers and pharmaceutical companies who have expressed their great need for it.

Initially launched for breast cancer in the Netherlands and the UK, Px is now developing OWise for all cancer types and plans to employ it swiftly across Europe, preferably with the aid of all 3 Phases of the present programme. Aim of Phase 1 project is to develop of a business plan to roll-out OWise in EU countries, reaching at least 1 million EU cancer patients annually in 2020, providing >20% of these with access to OWise while improving cancer outcomes through its PRO data analysis. Px’ revenues are expected to go up by 30% by 2020, due to this programme.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "OWISE4EU" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "OWISE4EU" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.4.;H2020-EU.2.1.1.;H2020-EU.2.3.1.;H2020-EU.3.1.6.)

CLINICOVERY (2018)

CLINICOVERY, a versatile, high quality, environmental-friendly, easy to use e-Clinical solution for clinical research

Read More  

ImmuneHunter (2017)

Bioinformatics platform for profiling of health: allowing early and accurate detection of multiple diseases simultaneously

Read More  

SensUS (2018)

SensUS: A non-invasive and quantitative ultrasound (QUS) device for an objective monitoring of the childbirth labour process.

Read More